Zevor-cel for Multiple Myeloma

Recruiting in Palo Alto (17 mi)

+13 other locations

Overseen byShaji Kumar, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Carsgen Therapeutics, Ltd.

No Placebo Group

Trial Summary

What is the purpose of this trial?A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

Eligibility Criteria

This trial is for adults aged 18-79 with relapsed/refractory multiple myeloma who've had specific prior treatments and are not responding to their last therapy. They must have good organ function, no recent major surgery or cancer treatments, no active infections like HIV/HBV/HCV, and agree to use contraception for a year post-treatment.

Inclusion Criteria

I am fully active or can carry out light work.

Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception for at least 12 months after T cell infusion

My blood, kidney, and liver tests are within normal ranges.

+9 more

Exclusion Criteria

I am unable or unwilling to follow the clinical trial requirements.

I still have side effects from past treatments that haven't gone away.

I have taken steroids before my cell collection or before reducing my white blood cells.

+17 more

Participant Groups

The study tests Zevor-cel (CT053), a CAR T-cell therapy targeting BCMA in patients whose multiple myeloma has returned or resisted treatment. It's an early-stage trial assessing the safety and effectiveness of this new intervention.

1Treatment groups

Experimental Treatment

Group I: CAR-BCMA T CellsExperimental Treatment1 Intervention

Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.